NasdaqGS:SVRABiotechs
A Look At Savara (SVRA) Valuation After Strong 1 Year Shareholder Return
Recent share performance and business profile
Savara (SVRA) has drawn attention after a month return of about 12%, following a relatively flat past 3 months. The move comes as investors reassess this US$1.5b clinical stage rare disease developer.
See our latest analysis for Savara.
Despite a softer 1-day share price return of 3.29% and a 7-day share price return of 1.18%, Savara’s 12.24% 30-day share price return sits alongside a very large 1-year total shareholder return of around 100%,...

